Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

E-site drug specificity of the human pathogen Candida albicans ribosome

Science Advances(2022)10.1126/sciadv.abn1062Source: DataRank Database

E-site drug specificity of the human pathogen Candida albicans ribosome is a research paper published in Science Advances (2022). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

Linked data & code

emdb pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.32)OA: goldTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

O A Kolosova ORCID,Artem Stetsenko ORCID,Cheng Wu ORCID,David Bruchlen ORCID,Konstantin S. Usachev ORCID

Live enrichment

PubMed:35613268 PMC:PMC9132455 OpenAlex:https://openalex.org/W4281476264

Dutch Research Council (NWO)

Grant: 184.034.014

Netherlands Electron Microscopy Infrastructure (NEMI)

National Institutes of Health

Grant: 1R21AI138158-01

Determining genetic signatures of the cryptococcal response to Zoloft by an integrated approach combining transcriptome, translatome and genetic screens

FWCI

2.32

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: CC BY NC

journalhttps://www.science.org/doi/pdf/10.1126/sciadv.abn1062?download=true

GOLDhttps://www.science.org/doi/pdf/10.1126/sciadv.abn1062?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/sciadv.abn1062?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/sciadv.abn1062

journalhttps://doi.org/10.1126/sciadv.abn1062

Fields of Study

Antifungal resistance and susceptibilityFungal Infections and StudiesRNA and protein synthesis mechanismsMedicineBiologyChemistry0301 basic medicine0303 health sciences03 medical and health sciencesAntifungal AgentsBinding SitesCandida albicansCryoelectron MicroscopyHumansRibosomes

MeSH Terms

Antifungal AgentsBinding SitesCandida albicansHumansRibosomesCryoelectron Microscopy

Keywords

Candida albicansRibosomeMicrobiologyAngstromDrug resistanceHuman pathogenA-siteBiologyAntifungal drugBinding siteCorpus albicansRibosomal binding sitePathogenRibosomal RNARibosomal proteinFungusTransfer RNACycloheximideChemistryRNABiochemistryBacteriaProtein biosynthesisGeneticsCrystallographyAntifungal AgentsBinding Sites[SDV.BBM.BS] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM]Cryoelectron MicroscopyHumansBiomedicine and Life Sciences[SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/MycologyRibosomes

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being